Nivolumab/Pembrolizumab

Reactions Weekly 2026

View at publisher

DOI: 10.1007/s40278-026-92011-6

Cited by: 0

References: 1

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Pharmacovigilance and Adverse Drug Reactions Immunotherapy and Immune Responses

References 1